about
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementAdvances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert ForumEffect of the antipsychotic agent amisulpride on glucose lowering and insulin secretionOlanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.Metabolic Effects of Antidepressant TreatmentMetabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.Cholesterol and triglycerides in antipsychotic-naive patients with nonaffective psychosis.Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.The prevalence of metabolic syndrome amongst patients with severe mental illness in the community in Hong Kong--a cross sectional study.Newer molecules in the treatment of schizophrenia: A clinical updateThe efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese populationOlanzapine use for the adjunctive treatment of adolescents with anorexia nervosaBody mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.Metformin and berberine prevent olanzapine-induced weight gain in ratsThe benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial.Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychoticsDoes Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study.Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical TrialCardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness.Effectiveness of sulpiride in adult patients with schizophrenia.Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialMetabolic syndrome in people with schizophrenia: a review.A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics.Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.Drugs in development for the treatment of schizophrenia.Promoting physical health in youth mental health services: ensuring routine monitoring of weight and metabolic indices in a first episode psychosis clinic.Weight gain associated with taking psychotropic medication: an integrative review.Weight gain and lipid-glucose profiles among patients taking antipsychotic medications: comparisons for prescriptions administered using algorithms versus usual care.Potential biomarkers in psychiatry: focus on the cholesterol system.Positioning mental health nursing practice within a positive health paradigm.Physical health inequities in people with severe mental illness: identifying initiatives for practice change.Acute hyperglycemia associated with short-term use of atypical antipsychotic medications.Role of atypical antipsychotics in the treatment of generalized anxiety disorder.Pharmacogenetics of second-generation antipsychotics.Concomitant Use of Topiramate Inducing Neutropenia in a Schizophrenic Male Stabilized on Clozapine.Treatment of clozapine-associated weight gain: a systematic review.Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience.
P2860
Q26783003-510DD41D-7C3B-4E82-863B-6C6431752D8EQ26784022-9B1A6F71-F7EA-4750-974D-E732B0D90AEBQ28252428-9D2F782D-EB2B-482F-9E36-32B3171FB97EQ33673618-625DC5AD-A69F-4A73-94E0-CD765B996846Q33712365-B4C05B5E-0548-43F7-9696-25DFCBEE00C7Q34037969-20632E76-7169-410A-9028-181C3FA91FCAQ34289026-EAF617D1-3176-42B5-A032-7FD2BFD41F52Q34620547-F5337E7F-2ABB-44F1-96EE-142914901D10Q34623350-F9DEEA64-61B8-46BF-95EC-907639EAB417Q34626443-6F32A9D3-AA48-45C3-89C7-6965EF04B97BQ34843883-8E24E805-7BE8-45CA-A566-679BFB1BC903Q35021287-71480BE9-14D0-4A91-A731-DF7FD3592C24Q35036803-E07DE3B0-5223-4E8D-B139-AF34E143015FQ35100107-F0A441B5-D9C5-46C3-AF9F-3D1601F3F526Q35131343-C0899074-F92F-42B0-AF15-D6CF29BEB12FQ35154166-09AC8F0E-2F2E-4C20-AEE9-F254AF5F6A3AQ35330607-B5FC9D1F-6674-4BA7-B7D1-3F7D9B86F640Q35843293-3DF832E2-ACA1-4221-9056-C519AAE5DF78Q36136886-DEA138EA-1740-47EC-9327-BD51ADEB96EAQ36198276-A39379EA-1042-49A2-9E63-28A687C22C57Q36202865-D9362570-CA8E-4F0C-A4F6-3CD81C7474B1Q36421831-B936D533-4D73-423B-88F0-EF810CFB1888Q36770037-6CF67ECA-DD4E-4547-83E6-76CF8317CD7CQ37078993-908E192C-CE66-496B-8D2F-C14C5B6DA3B5Q37129646-F0BC04FA-65AD-47AF-9CF4-AA4AAC486CFCQ37233215-09071D64-26AC-4B9F-AF29-DEC48B421D77Q37328780-91D20520-3DF1-4370-BFA9-1631193FAEEDQ37546125-E35F4F00-C8C7-4294-85F5-059C2BD9BF94Q37791558-34E4AEEB-88F6-4DA0-8698-E2D9EAF4CF66Q37865068-75DE348F-052F-4627-9561-4D4DB7F565ECQ37954382-3AFF45E3-7653-4CDD-B593-8ABBCA6D5A51Q37981261-744C3665-16C6-4F85-8BAF-BBDB43BCAB59Q38047406-B2102C02-2025-40FB-955A-ABFDA7027099Q38165979-A91D9070-BC1A-4FB2-902E-8428AF27C969Q38176569-F136751F-D5A3-4681-84DD-166CD58287E7Q38209188-2BA63420-A325-4502-9D62-9E5F57D1D8B3Q38217628-7A04C7E5-A7FA-4DC9-8088-930A21D5A2A5Q38283039-771FA187-997E-4FDC-B9B1-97202616442CQ38334922-B01C2C48-9A3E-4E6F-A632-7A7AEE9C0CF8Q38430215-7ACFF85A-9472-4474-B439-7A4D35122E0D
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Metabolic side effects of antipsychotic medication.
@en
type
label
Metabolic side effects of antipsychotic medication.
@en
prefLabel
Metabolic side effects of antipsychotic medication.
@en
P2093
P2860
P1476
Metabolic side effects of antipsychotic medication.
@en
P2093
Ebenbichler CF
Fleischhacker WW
Rettenbacher M
Tschoner A
P2860
P304
P356
10.1111/J.1742-1241.2007.01416.X
P577
2007-08-01T00:00:00Z